Rheonix Receives EPA Funding to Complete the Development of an Automatic Biosensor for Waterborne Pathogens

Ithaca, N.Y. — March 17, 2009 — Rheonix Inc., a privately-held biomedical device company known for its revolutionary, microfluidic, in vitro diagnostic platform, announced an additional $120,000 award from the U.S. Environmental Protection Agency (EPA) to further commercialize its biosensor technology for the rapid detection of Cryptosporidium parvum in drinking water.

Cryptosporidium parvum can cause serious illness in infants and the elderly. The largest outbreak of the infection occurred in Milwaukee in 1993 when over 100 individuals died as a result of drinking contaminated water.

Rheonix will use this funding to transfer manual testing onto its fully-automated microfluidic device known as the CARD™ (Chemistry And Reagent Device) platform. The CARD™ automatically performs all sample preparation, analysis, and readout functions with no hands-on effort. The test results will be achieved in considerably less time and with less expense than current solutions. Rheonix will also work with the Battelle, which will perform an independent verification of the technology in cooperation with the EPA's Environmental Technology Verification (ETV) Program.

Richard Montagna, Ph.D., Senior Vice President for Scientific Affairs and the Principal Investigator for the EPA program, commented, “We are extremely pleased that the EPA has shown its continued support and confidence in our technological approach. We are confident that we will soon be able to provide an inexpensive and effective alternative to the cumbersome methods currently used to test the safety of drinking water.” Tony Eisenhut, President of Rheonix, explained, “The validation of our technology and capabilities by the EPA is an important step in our Company’s growth. This additional funding will not only allow us to fully automate the test procedure, but will also strengthen our active efforts to identify a suitable marketing partner.” He went on to say, “Our staff is committed to meeting or exceeding the Agency’s expectations to provide innovative solutions for the improved safety of the U.S. drinking water supply.”

Rheonix receives FDA Emergency Use Authorization for Automated COVID-19 Test.
Learn More